SMARCA4

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Retrieved on: 
Thursday, February 15, 2024

WILMINGTON, Del., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2023, and outlined key objectives for 2024.   

Key Points: 
  • “Our partnership with AbCellera represents a strategic step to expand our pipeline, based on our core competencies in medicinal chemistry, cancer biology and clinical development.
  • A second cohort of patients with AML is expected to initiate in the first half of 2024.
  • Under the terms of the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize products emerging from the collaboration.
  • The decrease in general and administrative expenses was primarily due to our continued management of general and administrative expenses.

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Retrieved on: 
Wednesday, November 1, 2023

WILMINGTON, Del., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today provides strategic pipeline updates and reports third quarter financial results.

Key Points: 
  • Given the overlap with the CDK9 program, Prelude does not plan to advance PRT1419 further at this time.
  • Given the focus of the Company on SMARCA2 and CDK9, Prelude will not advance the program further and is actively pursuing further clinical development with external partners.
  • “We made significant progress in the third quarter with our four clinical stage molecules and, as planned, conducted a rigorous assessment of each program.
  • We expect our R&D expenses to vary from quarter to quarter, primarily due to the timing of our clinical development activities.

SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit

Retrieved on: 
Tuesday, October 31, 2023

KOREA and KING OF PRUSSIA, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SK Life Science Labs (formerly Proteovant Therapeutics) a subsidiary of SK Biopharmaceuticals, today will present preclinical data supporting its SMARCA protein degradation discovery program at the 6th Annual Targeted Protein Degradation (TPD) Summit.

Key Points: 
  • KOREA and KING OF PRUSSIA, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SK Life Science Labs (formerly Proteovant Therapeutics) a subsidiary of SK Biopharmaceuticals, today will present preclinical data supporting its SMARCA protein degradation discovery program at the 6th Annual Targeted Protein Degradation (TPD) Summit.
  • SK Life Science Labs integrates its AI-enabled target ID platform, protein degrader discovery and development expertise, and MOPED™ molecular glue screening platform to identify and advance novel protein degraders.
  • “Today’s presentation unveils new data that showcase SK Life Science Labs’ unique approach to discovering compounds with the potential to change the future of cancer therapeutics,” said Donghoon Lee, President and CEO of SK Biopharmaceuticals, SK Life Science Inc., and SK Life Science Labs.
  • “Since acquiring SK Life Science Labs earlier this year, we have been focused on leveraging the company’s R&D capabilities and supporting its promising programs.

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference 

Retrieved on: 
Saturday, October 14, 2023

and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA.

Key Points: 
  • and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA.
  • The four Prelude poster presentations include data from two ongoing Phase 1 clinical trials for Prelude’s CDK9 inhibitor, PRT2527, and CDK4/6 inhibitor, PRT3645, and two preclinical posters for our SMARCA2 degrader compound, PRT3789.
  • Initial clinical data from first three dose escalation cohorts (20, 40 and 80 mg QD) were reported.
  • We look forward to the translation of these preclinical results in clinical readouts planned for 2024,” said Peggy Sherle, Ph.D., Chief Scientific Officer of Prelude Therapeutics.

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 3, 2023

WILMINGTON, Del., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Key Points: 
  • Recent equity financing extends cash runway into 2026, enabling advancement of Prelude’s pipeline through critical milestones
    WILMINGTON, Del., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
  • The Company intends to provide a program update by year end and present initial results at a future scientific meeting.
  • Research and Development (R&D) Expenses: For the second quarter of 2023, R&D expense increased to $25.0 million from $21.3 million for the prior year period.
  • General and Administrative (G&A) Expenses: For the second quarter of 2023, G&A expenses decreased to $7.4 million from $8.2 million for the prior year period.

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 15, 2023

WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2022, and provided a corporate update.   

Key Points: 
  • Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged through Q4 2024
    WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2022, and provided a corporate update.
  • “We made considerable progress in 2022, including the filing and acceptance of two new INDs for our next generation CDK4/6 inhibitor and our first-in-class, highly selective SMARCA2 degrader.
  • Initial data from PRT2527 and PRT1419 demonstrate encouraging safety, favorable pharmacokinetic and pharmacodynamic profiles in solid tumors, and support continued advancement in hematological cancers.
  • Title: A phase 1, open-label, multicenter, dose-escalation study of PRT2527, a cyclin-dependent kinase 9 (CDK9) inhibitor, in adult patients (pts) with advanced solid tumors.

Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 5, 2022

Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

Key Points: 
  • Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III
    The poster will be accessible following the presentation under the Science section of the Company’s website.
  • In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors.
  • Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.
  • Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 14, 2022

WILMINGTON, Del., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent clinical and development pipeline progress.

Key Points: 
  • I believe these programs offer the best chance to improve patient outcomes and I share our investigators excitement in our highly differentiated molecules.
  • Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents, and marketable securities as of September 30, 2022, were $224.0 million.
  • Prelude anticipates that its existing cash, cash equivalents and marketable securities will be sufficient to fund Preludes operations into the fourth quarter of 2024.
  • We expect our research and development expenses to vary from quarter to quarter, primarily due to the timing of our clinical development activities.

Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting

Retrieved on: 
Wednesday, November 9, 2022

The meeting will be held November 812, 2022, at the Boston Convention and Exhibition Center and virtually.

Key Points: 
  • The meeting will be held November 812, 2022, at the Boston Convention and Exhibition Center and virtually.
  • The poster will highlight new data demonstrating the potential of FHD-286, in combination with an anti-PD-1 antibody, to provide synergistic efficacy and survival benefit compared to anti-PD-1 alone in preclinical models.
  • In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors.
  • Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

Retrieved on: 
Tuesday, October 18, 2022

Preclinical models with SMARCA4 deletions demonstrated that selective degradation of SMARCA2 with our potent and highly selective molecule PRT3789, resulted in significant anti-tumor activity at well tolerated doses, said Dr. Peggy Scherle, Chief Scientific Officer of Prelude.

Key Points: 
  • Preclinical models with SMARCA4 deletions demonstrated that selective degradation of SMARCA2 with our potent and highly selective molecule PRT3789, resulted in significant anti-tumor activity at well tolerated doses, said Dr. Peggy Scherle, Chief Scientific Officer of Prelude.
  • Historically, structural similarities between members of the SMARCA family have made it challenging to selectively inhibit SMARCA2.
  • Clearance of the IND for PRT3789 represents a major milestone for Prelude Therapeutics, as we advance our first-in-class SMARCA2 protein degrader from discovery to the clinic.
  • Preludes pipeline includes five candidates currently in clinical development: PRT811, a highly selective, potent, orally bioavailable PRMT5 inhibitor; PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a brain penetrant CDK4/6 inhibitor, and PRT3789, a SMARCA2/BRM protein degrader.